비엠피-2와 에이치에스브이-티케이 자살유전자를 동시에 포함하고 발현 할 수 있도록 하는 벡터와 이 벡터가 도입된 자가조절형 줄기세포 치료제
    13.
    发明公开
    비엠피-2와 에이치에스브이-티케이 자살유전자를 동시에 포함하고 발현 할 수 있도록 하는 벡터와 이 벡터가 도입된 자가조절형 줄기세포 치료제 有权
    包括BMP-2和SUICIDE基因组成的DNA盒的载体HSV-TK和表达BMP-2和HSV-TK的自调节干细胞药物

    公开(公告)号:KR1020110005336A

    公开(公告)日:2011-01-18

    申请号:KR1020090062796

    申请日:2009-07-10

    Inventor: 성영철 박상훈

    Abstract: PURPOSE: A vector which contains and expresses BMP-2 and HSV-tK suicide gene and a stem cell therapeutic agent of self-regulation in which the vector is introduced are provided to remove cancer occurrence possibility and to reduce in vivo immunodepression. CONSTITUTION: A DNA cassette comprises a nucleic acid sequence of BMP and nucleotide acid of suicide gene between transcription/translation initiator sequence. The BMP has a nucleic acid sequence of human BMP-2 of sequence number 1. The suicide gene is HSV-tk having a nucleic acid sequence of sequence number 3. An expression vector has the DNA cassette. A stem cell therapeutic agent of self-regulation contains mesenchymal stem cells as an active ingredient, obtained by proliferation of recombinant adenovirus-infected stem cells. The therapeutic agent is used for treating bone diseases.

    Abstract translation: 目的:提供含有和表达BMP-2和HSV-tK自杀基因的载体和引入载体的自我调节干细胞治疗剂,以消除癌症发生的可能性并减少体内免疫抑制。 构成:DNA盒包含BMP的核酸序列和转录/翻译起始序列之间的自杀基因的核苷酸。 BMP具有序列号1的人BMP-2的核酸序列。自杀基因是具有序列号3的核酸序列的HSV-tk。表达载体具有DNA盒。 自体调节干细胞治疗剂含有间充质干细胞作为活性成分,通过重组腺病毒感染干细胞的增殖获得。 治疗剂用于治疗骨病。

    신규 급성 골수성 백혈병 진단용 바이오마커 및 이의 항체를 이용한 치료제
    14.
    发明公开
    신규 급성 골수성 백혈병 진단용 바이오마커 및 이의 항체를 이용한 치료제 无效
    新生物标志物特异性的急性麻痹性紫癜和使用抗体的药物

    公开(公告)号:KR1020100035404A

    公开(公告)日:2010-04-05

    申请号:KR1020080094775

    申请日:2008-09-26

    CPC classification number: C12Q1/6886 A61K39/395 G01N33/57426

    Abstract: PURPOSE: A novel biomarker for acute myeloid leukemia is provided to diagnose acute myeloid leukemia and neutralize by specifically binding to biomarker. CONSTITUTION: A biomarker for diagnosing acute myeloid leukemia contains TM6SF1(transmembrane 6 superfamily member 1) or TM7SF3(transmembrane 7 superfamily member 3) as an active ingredient. An extracellular domain of TM6SF1 specifically binds to anti-TM6SF1 antibody. The extracellular domain of TM6SF1 is encoded by a sequence of sequence number 5. An extracellular domain of TM7SF3 specifically binds to anti-TM7SF3 antibody. The extracellular domain of TM7SF3 is encoded by a sequence of sequence number 6.

    Abstract translation: 目的:提供急性骨髓性白血病的新型生物标志物,用于诊断急性骨髓性白血病,并通过特异性结合生物标志物中和。 构成:用于诊断急性骨髓性白血病的生物标志物含有作为活性成分的TM6SF1(跨膜6超家族成员1)或TM7SF3(跨膜7超家族成员3)。 TM6SF1的细胞外结构域特异性结合抗TM6SF1抗体。 TM6SF1的细胞外结构域由序列号5的序列编码。TM7SF3的胞外结构域特异性结合抗TM7SF3抗体。 TM7SF3的细胞外结构域由序列号6的序列编码。

    유전자 전달 효율이 개선된 재조합 아데노바이러스 및리포좀을 포함하는 조성물
    15.
    发明公开
    유전자 전달 효율이 개선된 재조합 아데노바이러스 및리포좀을 포함하는 조성물 无效
    包含重组腺病毒和脂质体的组合物与增强的基因转移

    公开(公告)号:KR1020090092536A

    公开(公告)日:2009-09-01

    申请号:KR1020080017837

    申请日:2008-02-27

    Abstract: A composition for improving gene transfer containing a recombinant adenovirus and DOTAP (1,2-dioleoyl-3-trimethylammonium propane) is provided to increase the gene transfer efficiency of recombinant adenovirus which expresses interleukin-12 mutant and have the excellent anticancer effect. A composition for enhancing gene transfer comprises a recombinant adenovirus and DOTAP(1,2-dioleoyl-3-trimethylammonium propane). The recombinant adenovirus expresses cytokine, chemokine, antigen, tumor suppressor gene, suicide gene, anti-angiogenic factor, prodrug activating gene or immunostimulatory gene.

    Abstract translation: 提供了一种用于改善含有重组腺病毒和DOTAP(1,2-二油酰-3-三甲基铵丙烷)的基因转移的组合物,以提高表达白细胞介素-12突变体并具有优异抗癌作用的重组腺病毒的基因转移效率。 用于增强基因转移的组合物包含重组腺病毒和DOTAP(1,2-二油酰-3-三甲基铵丙烷)。 重组腺病毒表达细胞因子,趋化因子,抗原,肿瘤抑制基因,自杀基因,抗血管生成因子,前药活化基因或免疫刺激基因。

    SIVmac239의 면역원성 플라스미드 및 이들을 함유한 AIDS DNA 백신
    17.
    发明公开
    SIVmac239의 면역원성 플라스미드 및 이들을 함유한 AIDS DNA 백신 失效
    SIVMAC239免疫球蛋白和含有其的艾滋病DNA疫苗

    公开(公告)号:KR1020090007670A

    公开(公告)日:2009-01-20

    申请号:KR1020080134992

    申请日:2008-12-26

    Inventor: 성영철 서유석

    Abstract: The immunogenic plasmid of SIVmac239(Simian Immunodeficiency Virus) is provided to minimize the immunity disturbance activity of the supplementary gene and optimize the codon to increase the expression efficiency of the inserted gene, thereby increasing the expression efficiency and immune efficacy of immunogen. The plasmid comprises the gene vif derived from SIVmac239, the signal sequence of secretory protein which is linked to the 3'-terminal of the gene vif, and the gene nef derived from SIVmac239 linked to the 5-terminal of the gene vif.

    Abstract translation: 提供SIVmac239(猿猴免疫缺陷病毒)的免疫原性质粒以最小化补充基因的免疫扰动活性,优化密码子以增加插入基因的表达效率,从而提高免疫原的表达效率和免疫功能。 该质粒包含衍生自SIVmac239的基因vif,与vif基因的3'末端连接的分泌蛋白的信号序列,以及源自与基因vif的5'端连接的SIVmac239的基因nef。

    유전자 전달 효율이 개선된 재조합 아데노바이러스 및폴리양이온을 포함하는 조성물
    18.
    发明公开
    유전자 전달 효율이 개선된 재조합 아데노바이러스 및폴리양이온을 포함하는 조성물 无效
    包含重组腺病毒的组合物和具有增强基因转移效率的聚合

    公开(公告)号:KR1020040073904A

    公开(公告)日:2004-08-21

    申请号:KR1020030009666

    申请日:2003-02-15

    Inventor: 성영철 연제인

    CPC classification number: C12N15/86 C12N2710/10041

    Abstract: PURPOSE: A composition comprising recombinant adenovirus and polycation with enhanced gene transfer efficiency is provided, thereby enhancing gene transfer, improving gene transduction and replicated amount of adenovirus within cells, so that effect of therapy can be improved. CONSTITUTION: The composition comprises recombinant adenovirus of which fiber is modified and polycation, wherein the recombinant adenovirus is AdG; and the polycation is polybrene, protamine sulfate, lipopectamine, DOTAP(1,2-dioleoyl-3- trimethylammonium-propane) and CaCl2, preferably protamine sulfate. A method for enhancing gene transfer efficiency of adenovirus comprises treating the recombinant adenovirus of which fiber is modified with polycation.

    Abstract translation: 目的:提供一种具有增强基因转移效率的重组腺病毒和聚阳离子的组合物,从而增强基因转移,改善细胞内基因转导和腺病毒复制数量,从而提高治疗效果。 构成:该组合物包含其纤维被修饰的重组腺病毒和聚阳离子,其中重组腺病毒是AdG; 聚阳离子是聚凝胺,硫酸鱼精蛋白,脂蛋白,DOTAP(1,2-二油酰-3-三甲基铵 - 丙烷)和CaCl 2,优选硫酸鱼精蛋白。 一种增强腺病毒基因转移效率的方法,包括用聚阳离子处理纤维被修饰的重组腺病毒。

    PD-L1 융합 단백질 및 이의 용도
    19.
    发明公开
    PD-L1 융합 단백질 및 이의 용도 审中-实审
    PD-L1融合蛋白及其用途

    公开(公告)号:KR1020150135148A

    公开(公告)日:2015-12-02

    申请号:KR1020150071820

    申请日:2015-05-22

    Abstract: 본발명은 PD-L1의세포외도메인과변형된면역글로불린 Fc 영역으로이루어진융합단백질에관한것이다. PD-L1의세포외도메인및 이의단편은우수한면역조절기능을가지고있으며, 변형된면역글로불린의 Fc 영역을결합시킬경우면역조절을위한약물로활용가능하다. 따라서, 본발명에따른 PD-L1 융합단백질은염증성장질환, 대장염, 건선, 천식및 관절염의질환모델에서그 효과가우수함을입증하였으므로, 상기질환의치료에매우효과적으로이용될수 있다.

    Abstract translation: 本发明涉及融合蛋白,其包含:程序性细胞死亡 - 配体1(PD-L1)的细胞外结构域; 和转化的免疫球蛋白的片段可结晶(Fc)区。 PD-L1的细胞外结构域及其片段具有突出的免疫调节功能。 如果结合转化的免疫球蛋白的Fc区,则可以应用PD-L1融合蛋白作为免疫调节药物。 因此,根据本发明的PD-L1融合蛋白在具有炎性肠病,结肠炎,牛皮癣,哮喘和关节炎的疾病模型中显示出优异的效果,从而能够用作疾病的有效治疗。

Patent Agency Ranking